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Abstract 
Background 
The pharmacokinetic (PK) parameters in animal models can help optimise novel 
candidate drugs prior to testing them in man. However, due to the complexity of PK 
experiments, their use is limited in academia. We present a novel surgical rat model 
for investigation of the PK parameters and its use in an anti-obesity drug development 
program. 
Materials and Methods 
The model uses anesthetised male Wistar rats, a jugular and a femoral catheter and an 
insulin pump for peptide infusion. The following PK parameters were measured; 
metabolic clearance rate (MCR), half-life, and volume of distribution (Vd). Glucagon-
like peptide 1 (GLP-1), glucagon (GCG) and exendin-4 (Ex-4) were used to validate 
the model. The PK parameters of anti-obesity drug candidates X1, X2 and X3 were 
then measured.  
Results 
GLP-1 had a significantly higher MCR (83.9±14.1 ml/min/kg) compared to GCG 
(40.7±14.3 ml/min/kg) and Ex-4 (10.1±2.5 ml/min/kg) (p<0.01 and p<0.001 
respectively). Ex-4 had a statistically significant longer half-life (35.1±7.4 min) 
compared to both GCG (3.2±1.7 min) and GLP-1 (1.2±0.4 min) (p<0.01 for both 
GCG and GLP-1). Ex-4 had a statistically significant higher Vd (429.7±164.9 ml/kg) 
compared to both GCG (146.8±49.6 ml/kg) and GLP-1 (149.7±53.5 ml/kg) (p<0.01 
for both GCG and GLP-1). Peptide X3 had a statistically significant longer half-life 
(21.3±3.5 min) compared to both X1 (3.9±0.4 min) and X2 (16.1±2.8 min) (p<0.001 
for both X1 and X2). 
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Conclusions 
We present an affordable and easily accessible platform for the measurement of the 
PK parameters of peptides. This novel surgical rat model produces consistent and 
reproducible results while minimising animal use. 
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Introduction 
The development of high throughput approaches to drug development studies has 
been driven by the advances in high-speed chemistry and pharmacological screening 
[1]. There is a constant need for screening more and more compounds as the safety 
precautions for new drugs and the market competition increase [2, 3]. 
Pharmacokinetics involves investigating the mechanism by which a substance is 
absorbed and distributed within the body, any metabolism of the substance within the 
body, and finally the effects and the routes of excretion of the substance and its 
metabolites from the body [4-6].  
In the drug development setting, PK parameters [half-life, metabolic clearance rate 
(MCR), volume of distribution (Vd)] are important as they allow characterisation of 
the relationship between drug dosage regimens and drug concentration-time profiles 
[7]. Over the last two decades, the use of PK modelling techniques to aid investigating 
the drug actions has become standard practice [8, 9]. Rodents, and in particular rats, 
are extensively used as experimental models for PK studies helping to optimise and 
select drugs prior to human trials [8, 10-15]. 
Drug discovery is extremely expensive with overall failure rates exceeding 80% while 
in the anti-obesity field the failure rates approach 99% [16-18]. Inadequate PK 
profiles and poor bioavailability of drug candidates are responsible for 10% of drug 
failures [19]. Pharmacokinetic experiments incur a significant cost (cost of the 
specialist equipment and consumables, purchasing and maintenance of animals, 
manpower and samples analysis cost) and these cost implications prevent many 
groups working on translational research from conducting PK studies during the 
discovery stages of drug development 
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An affordable PK animal model could significantly promote the use of PK early in 
drug development and potentially lead to a higher drug development success rate. As 
part of an anti-obesity drug discovery program we have successfully developed a 
surgical rat model for investigating the PK parameters of candidate drugs. The model 
includes cannulation of the right internal jugular vein, the left femoral vein and the 
use of a widely available, inexpensive, insulin pump for the intravenous (i.v.) 
infusion. In this study we present a surgical rat model for measuring the PK 
parameters of peptide drugs, its validation and the results obtained through its use. 
 
Materials and Methods 
The surgical rat model was used to measure the PK parameters of six peptides. 
Peptides GLP-1, GCG and Ex-4 were used to validate the model. Peptides X1, X2 and 
X3 were developed and tested as potential anti-obesity drug candidates. 
Peptides  
GLP-1, GCG and Ex-4 were purchased from Bachem, Ltd (Merseyside, UK) while 
peptides X1, X2 and X3 were synthesised by and purchased from Insight, Ltd 
(Wembley, UK). Peptides were synthesised using an automated 
fluorenylmethyloxycarbonyl solid phase peptide synthesis method with each amino 
acid sequentially added from the C to the N terminus. Peptides were cleaved from the 
resin then purified using reverse phase preparative high performance liquid 
chromatography (HPLC) followed by lyophilisation. All peptides supplied had a 
purity of >95% evaluated by HPLC. 
Animal studies 
All animal procedures undertaken were approved by the British Home Office under 
the UK Animal (Scientific Procedures) Act 1986 (Project Licence 70/7236). Adult 
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male Wistar rats (Charles River Ltd., Margate, Kent, UK) were maintained in double-
housed cages under controlled temperature (21-23
o
C) and light-dark cycles (12:12 
hour light-dark schedule, lights on at 0700).  Animals were allowed ad libitum access 
to water and ad libitum access to RM1 diet (Special Diet Services) unless otherwise 
stated. To minimise any non-specific stress effects animals were regularly handled to 
allow acclimatisation. 
Experiments 
The study design is shown in Figure 1. Animals were anesthetised with isoflurane, a 
catheter was inserted in the right jugular vein and a baseline sample was taken. The 
peptide to be tested (GLP-1, GCG or Ex-4) was reconstituted at a concentration of 
30nmol/mL, the pump and tubing loaded and primed with the peptide solution, prior 
to catheterising the left femoral vein. The pump was then connected to the femoral 
catheter and set at a flow rate of 0.3 ml/h and ran for 60 minutes. A single bolus dose 
of 1.5 nmol was administered just before the infusion only for Ex-4. Sampling 
through the jugular access was performed throughout the infusion and for 40 minutes 
post-infusion. Four animals were used for each peptide PK experiment. 
Equipment  
The pump used in this study was a Medtronic 407c insulin pump with a 1.0 ml 
reservoir (MMT-103A). The catheters used were polyethylene tubing (internal 
diameter (ID) 0.46 mm, outside diameter (OD) 0.91 mm) (Instech Solomon) [20].  
Catheter preparation 
All cannula tubing required was prepared before the start of the procedure. The 
catheter was cut to 12 and 10 cm length for the jugular and the femoral vein 
respectively. One end had a 1ml syringe with a 25 gauge needle attached to it. A 1ml 
syringe was filled with heparinised saline (100 I.U/ml) and attached to the needle. The 
Page | 8  
 
other end of the tube was cut with a scalpel blade to create a bevelled edge. Catheter 
implantation was performed with the help of surgical loupes with a magnifying force 
of 2.5-3.5x. 
Pump and peptide preparation 
Peptides were reconstituted in gelofusine (at a concentration of 30 nmol/mL) after the 
jugular catheter was inserted. The infusion pump was loaded and allowed to run for 
20 minutes in order to allow the peptide solution to fill the femoral catheter.  
Intravenous infusion lasted for 60 minutes with an infusion rate of 0.3 ml/h. 
Pump infusate concentration measurement 
After the removal of the femoral catheter from the femoral vein, the pump was 
allowed to run inside a microtube for 20 minutes and the infusate was collected and 
assayed by radioimmunoassay (RIA). Pump infusate concentration was used to 
calculate the total amount of peptide infused over 60 minutes.  
Sampling and hormone assays 
A baseline sample of 500 μl was taken following the insertion of a jugular vein 
cannulation. A total of 19 other sample were taken at the following time points from 
the beginning of peptide infusion: 0, 30, 35, 40, 45, 50, 55, 60, 62, 64, 66, 68, 70, 75, 
80, 85, 90, 95 and 100 minutes (Figure 1). 
Blood samples were collected in 1.5 ml heparinized microtubes containing a protease 
inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA, P2714). The tubes were then 
spun in a centrifuge (3-18K SciQuip, Sigma, USA) for 10 minutes at 3000g at 4
o
C. 
The plasma supernatant was collected and stored at -80ºC until assayed. 
Measurements of peptides concentration were carried out by established in-house RIA 
and all samples were tested in duplicate [21, 22].  
Anaesthesia 
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Animals were anaesthetised with gas anaesthetic (isoflurane via cone mask at 2%) 
with an appropriate gas scavenging system as previously described [23]. 
Jugular and femoral vein catheterisation 
Jugular and femoral vein catheterisation were performed as previously described [23].  
Calculations 
The PK properties that were investigated and calculated for each of the peptides 
included the half-life, the MCR and the Vd. All three peptides were tested at a 
concentration of 30 nmol/mL and at an infusion rate of 0.3 ml/h. Plasma peptide 
concentration was measured for 100 minutes after termination of the peptide infusion. 
Steady state concentration was calculated as the mean of the five values obtained at 
40, 45, 50, 55 and 60 minutes of the infusion phase. Peptide concentrations were 
plotted on a semi-logarithmic scale versus time and computed to yield the slope from 
which the half-life (t1/2) was determined.  
Plasma half-life was calculated as follows:  
gradient
ln(2)
=(min) t1/2    where ln(2) is the natural logarithm of 2 (0.693). 
The metabolic clearance rate (MCR) was calculated using Tait's formula:  
ionconcentratplasma  statesteady 
rate infusion 1) -min 1 -kg (ml MCR   
Volume of distribution (Vd) was calculated using following formula: 
)2ln(
2/1 MCRtVd     where ln(2) is the natural logarithm of 2 (0.693). 
Statistical analysis  
All data are expressed as the mean value ± SD. Comparisons of the PK parameters 
between the groups were performed using one-way analysis of variation (ANOVA) 
with Bonferroni’s post-hoc test.  In all cases, values of p<0.05 were considered 
Page | 10  
 
statistically significant. The following program was used for statistical analysis: 
(GraphPad Prism version 5.00 for Windows; GraphPad Software, San Diego, CA).  
 
Results 
The PK parameters of the peptides are shown in Table 1. The pre-infusion values 
(baseline levels) of GCG and GLP-1, were approximately 43 and 35 pmol/l 
respectively. The time-courses of the mean plasma concentrations of Ex-4, GLP-1 and 
GCG are shown in Figure 2 and those of X1, X2 and X3 are shown in Figure 3. 
Steady-state concentration levels were observed between 30 and 60 minutes after the 
start of the peptide infusion for all peptides. The steady-state concentration levels of 
Ex-4, GLP-1 and GCG were 16.8±4.2, 2.6±0.4 and 8.4±4.2 pmol/ml respectively 
(Table 1). Peptide X1 presented the highest steady-state concentration among all 
peptides tested in this study (28.7±13.6 pmol/ml).  
GLP-1 had a significantly higher MCR (83.9±14.1 ml/min/kg) compared to GCG 
(40.7±14.3 ml/min/kg) and Ex-4 (10.1±2.5 ml/min/kg) (p<0.01 and p<0.001 
respectively) (Figure 2). GCG had a significantly higher MCR than Ex-4 (p<0.01). 
Ex-4 had a statistically significant longer half-life (35.1±7.4 minutes) compared to 
both GCG (3.2±1.7 minutes) and GLP-1 (1.2±0.4 minutes) (p<0.01 for both GCG and 
GLP-1). 
Ex-4 had a statistically significant higher Vd (429.7±164.9 ml/kg) compared to both 
GCG (146.8±49.6 ml/kg) and GLP-1 (149.7±53.5 ml/kg) (p<0.01 for both GCG and 
GLP-1). 
Peptide X3 had a statistically significant longer half-life (21.3±3.5 minutes) compared 
to both X1 (3.9±0.4 minutes) and X2 (16.1±2.8 minutes) (p<0.001 for both X1 and 
X2) (Figure 3). 
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Discussion 
The surgical rat model presented in this study was developed and used as part of an 
anti-obesity drug development program in an academic setting. Three different 
peptides (GLP-1, GCG and Ex-4) were used to validate the model by measuring their 
PK parameters and comparing the results to previous published studies. Following 
results validation, the model was used to measure the PK parameters of 3 novel anti-
obesity drug candidates for humans. The rat model shown here has been used to 
characterise the PK parameters of more than 50 drug candidates in >200 rats in our 
experience, producing consistent and reliable results (data not shown due to 
intellectual property restraints).  
The PK properties of drug candidates are important for the designing of new and 
improved agents and they can only be calculated by in vivo experiments in animal 
models. Following validation of our rat model, we measured the PK parameters of 
drug candidates X1, X2 and X3.  
The validation of our model was centred on being able to measure the PK parameters 
of native peptide hormones. The three peptides used, GCG, GLP-1 and Ex-4, were 
selected due to the widely different PK parameters that they present and their 
relevance to the target drug candidate of our anti-obesity drug discovery program.  
The PK parameters of GCG, GLP-1 and Ex-4 as reported by this rat model fall well 
within what has been previously reported [10, 24, 25]. The half-life of GLP-1 reported 
by Oshima et al. in 1988 (39.5 min) is considered to be outside normal limits; the 
potential sources of error of that study include the frequent sampling resulting in 
cardiovascular instability (five samples, 1 ml each, were collected within a period of 
10 min and after centrifugation the suspension of red cells was reinfused into the 
animal) [21].  
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The selection of the time-points and volumes of sampling in our paradigm allows for 
consistent and reproducible measurement of the PK parameters while minimising 
blood loss and cardiovascular effects. We have previously reported that the total 
mortality rate in our experience was 0.5% (2/200 rats) [23].  
As the field of drug development keeps expanding and the importance of PK studies 
has become more widely accepted, reports of serial blood sampling and analysis for 
drug and/or drug metabolites have appeared in the literature with increasing frequency 
[26]. Regulatory requirements for accurate PK profiles of novel compounds is driving 
forward the development and refinement of methodology for determining plasma time 
course data for drugs and/or drug metabolites in rodents.  
The development of an animal model for investigating the PK properties of drug 
candidates in a drug development program is a complex task and requires multiple 
critical decisions to be made including the species/strain of animals that is 
representative of human, the i.v. routes that best serve the PK properties that are 
investigated, the number and time-points of obtaining the blood samples, the 
compound dose, the duration/rate of the infusion and the use of a reliable delivery 
system. 
The basic concept underlying the presented surgical rat model is that there are two 
different intravenous (i.v.) routes required [27, 28]. The first route is used for infusing 
the drug with the help of a pump and the second one is required for blood sampling. 
Previously different routes of i.v. access have been used, the most common routes 
include the jugular vein, the femoral vein and artery, the saphenous vein and the 
carotid artery; each route has its own advantages and disadvantages (Table 2) [10, 11, 
15, 25].  
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In our experience, the use of carotid arteries for sampling requires a higher degree of 
technical abilities and a longer learning curve. Furthermore, in case of encountering 
technical difficulties in catheter insertion, blood loss might be higher due to the 
increased pressure in the arterial system in comparison to the venous one. The 
saphenous vein presents the advantage of being close to the surface, thus reducing the 
amount of dissection to locate it, however its small size makes the catheterisation 
process a challenge.  
The femoral vein, in the authors’s view presents some important advantages. It is 
straightforward to locate as it is found in a bundle, together with the femoral artery 
and the femoral nerve. It has an adequate diameter to allow easy insertion of catheters 
and it can be exposed along its course so that more than one venotomies can be 
attempted if initial attempt fails. Of course, dissecting free the femoral vein from the 
femoral artery is challenging and great care should be taken not to damage the artery. 
The use of the jugular vein for sampling is one of the preferred methods due to the 
proximity of the jugular vein to the surface and its distance from any other major 
vessels.  
A point worth noting, based on our experience, is that catheters should be secured 
with the use of more than one ties, in particular the ones used for sampling over the 
ones used for infusing and whenever multiple samples over a long period of time are 
to be taken. The use of a single tie to stabilise the catheter has quite often proved 
inadequate resulting in the dislodgement of the catheter and inability to continue 
taking samples. One or two extra ties are not time-consuming and provide much more 
reassurance for uninterrupted blood sampling.   
Other equipment routinely used by the authors include a reusable cautery pen and 
magnifying loupes. The use of the cautery pen allows for easy and rapid hemostasis, 
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minimising blood loss and in experienced hands can also be used for dissection, 
minimising operating time. Surgical loupes have proved valuable especially while 
climbing the learning curve of femoral vein catheterisation but also afterwards and 
their magnification is of the essence whenever the first catheterisation attempt fails 
and the vessel collapses making the localisation of the venotomy site difficult.  
The advantages presented by the use of the proposed animal model for evaluating the 
PK properties of peptides include the affordability of the pump setting (pump and 
reservoir) due to its low cost which bypasses the need for an expensive dedicated 
pump system. The rest of the consumables used are easily accessible and the setting 
of the procedure can be relatively easily reproduced. At the same time the design of 
the study has been optimised to measure the PK properties of gut hormones or 
analogues developed based on gut hormones. Although our model was optimised for 
measurement of anti-obesity drug candidates based on gut hormones, it can be used 
for any type of PK experiments. 
A limitation of the current setting is the limited infusion rate that the insulin pump 
offers. Being originally designed to deliver small quantities of insulin in humans, the 
Medtronic 407c pump has a maximum rate of infusion of 0.35ml/h. This may pose 
limitations to researchers who wish a faster infusion rate. 
In summary, the proposed rat model provides an affordable and easily accessible 
platform for measuring the PK properties of peptides outside the facilities of large 
pharmaceutical industries. The authors feel that the surgical rat model for the 
measurement of the PK parameters of peptides described in this study can be a useful 
tool that can produce consistent and reproducible results while minimising animal use. 
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Table 1: Comparison of PK properties (metabolic clearance rate, half-life and volume of distribution) and of the steady-state 
concentration of glucagon, GLP-1, exendin-4, X1, X2 and X3 peptides, as measured in the surgical rat model (n=4).  
 
 
Glucagon GLP-1 Exendin-4  X1 X2 X3 
 Mean (SD) Mean (SD) Mean (SD)  Mean (SD) Mean (SD) Mean (SD) 
Metabolic clearance rate (ml/min/kg)  40.7 (14.3) 83.9 (14.1) 10.1 (2.5)  13.9 (8.1) 6.2 (3.5) 5.4 (0.2) 
Half-life (min)  3.2 (1.7) 1.2 (0.4) 35.1  (7.4)  3.9 (0.4) 16.1 (2.8) 21.3 (3.5) 
Volume of distribution (ml/kg)  146.8 (49.6) 149.7 (53.5) 429.7  (164.9)  81.6 (70.7) 141.9 (43.6) 164.1 (31.3) 
Steady state concentration (pmol/ml) 8.4 (4.2) 2.6 (0.4) 16.8 (4.2)  28.7 (13.6) 14.0 (4.2) 24.9 (0.9) 
GLP-1: Glucagon-like peptide 1, SD: Standard deviation, Values are shown as mean ± SD. 
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  Table 2: Published literature of the PK parameters of exendin-4, glucagon and GLP-1 in rats. 
Peptide Authors/Date Species 
Weight 
(g) 
Route 
Dura
tion 
Dose MCR Half-life (min) Vd (Css) nM 
Ex-4 
Young et 
al./2001 
Male                            
Sprague-
Dawley 
rats 
350-370 
Infusion: R. 
Saphenous V.  
Sampling: 
R.Femoral A. 
180 
min 
 0.05, 0.5, 5, 
and 50 
nmol/h  
0.5 nmol: 8.3±0.7 ml/min                                  
5 nmol: 4.8±0.4 ml/min                       
50 nmol: 3.7±0.5 ml/min 
0.5 nmol: 28±5                 
5 nmol: 40±5                  
50 nmol: 49±7 
- 
0.5 nmol: 
1.1±0.1                  
5 nmol: 
19±1.9                  
50 nmol: 
262±60 
GCG 
Emmanouel et 
al./1978 
Male  
Sprague-
Dawley 
rats 
250-350 
Infusion: Jugular 
V.   Sampling: 
Carotid A. 
  2-10 ng/min 31.8±1.2 ml/min/kg  -  -  - 
Kervran et 
al./1990 
Male 
Wistar rats 
250-280 
Infusion: 
Saphenous V.   
Sampling: 
Carotid  
45 
min 
0.56 nmol 36±5 ml/min/kg 1.9±0.1 
0.1±0.
01 
L/kg 
 - 
Oshima et 
al./1988 
Male 
Wistar rats 
500-550 
Infusion: 
Femoral V.  
Sampling: 
Jugular V. 
60 
min 
2 ug 46.7±13.3 ml/min/kg 5.8±1.0 
0.24±
0.07 L 
 - 
GLP-1 
Young et 
al./2001 
Male                            
Sprague-
Dawley 
rats 
350-370 
Infusion: R. 
Saphenous V.  
Sampling: 
R.Femoral A. 
180 
min 
0.05, 0.5, 5, 
and 50 
nmol/h  
0.5 nmol: 35±11 ml/min                    
5 nmol: 34±4 ml/min                             
50 nmol: 38±3 ml/min 
0.5 nmol: 1.2±0.9                                                                                   
5 nmol: 0.9±0.6                                                                                  
50 nmol: 0.5±0.2 
- 
0.5 nmol: 
0.32±0.06                  
5 nmol: 
2.49±0.45                  
50 nmol: 
20.53±2.94 
Oshima et 
al./1988 
Male 
Wistar rats 
500-550 
Infusion: 
Femoral V.  
Sampling: 
Jugular v. 
60 
min 
100 ug 18.6±8.6 ml/min/kg 39.5±15.5 
0.5±0.
1 L 
 - 
Ex-4: exendin-4, GCG: glucagon, GLP-1: glucagon-like peptide 1, Css: Steady-state concentration, “-” signifies that the respective parameter was not reported.  
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Figure 1: Graphical representation of the study design of the surgical rat model 
in anesthetised male Wistar rats. Plasma sampling points are displayed in black 
circles over time in minutes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1
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Figure 2: Plasma concentrations of glucagon, GLP-1 and exendin-4, and their 
pharmacokinetic parameters (metabolic clearance rate, half-life and volume of 
distribution) using the surgical rat model in anesthetised male Wistar rats. A: 
Semi-logarithmic plasma concentration of peptides over time, B: Metabolic 
clearance rate of peptides, C: Half-life of peptides and D: Volume of distribution 
of peptides. For all experiments n=4. Statistics with one-way ANOVA. ** 
=p<0.01, ***=p<0.001.  
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Figure 3: Plasma concentrations of peptides X1, X2 and X3, and their 
pharmacokinetic parameters (metabolic clearance rate, half-life and volume of 
distribution) using the surgical rat model in anesthetised male Wistar rats. A: 
Semi-logarithmic plasma concentration of peptides over time, B: Metabolic 
clearance rate of peptides, C: Half-life of peptides and D: Volume of distribution 
of peptides. For all experiments n=4. Statistics with one-way ANOVA. 
***=p<0.001. 
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